News

The Centers for Medicare & Medicaid Services released a guide to help laboratories apply for Clinical Laboratory Improvement Amendments certification, which includes information on the expedited review process implemented for the COVID-19 public health emergency.

States and COVID-19 testing laboratories have reported more than 277,000 COVID-19 cases in school-aged children since March, with about twice as many cases in children aged 12-17 than younger children, the Centers for Disease Control and Prevention reported.

The COVID-19 pandemic has brought increased attention to the issue of health care disparities. And it’s clear we’ve got a lot of work ahead of us to close the gaps.

American Organization for Nursing Leadership Board Chair Mary Ann Fuchs welcomed nearly 3,000 attendees to AONL 2020, which was held virtually.

Kaufman Strategic Advisors Managing Director Nate Kaufman responded to the RAND Corporation’s flawed and incomplete hospital pricing survey in a new analysis published.

The Centers for Medicare & Medicaid Services announced premium and cost-sharing information for Medicare Advantage and Part D prescription drug plans for the 2021 calendar year.

The Food and Drug Administration released a final rule allowing states, territories and Indian tribes to establish programs to import certain FDA-approved prescription drug and biological products from Canada.

President Trump signed an executive order on a number of health care issues, including protecting people with pre-existing medical conditions from insurance discrimination and ending surprise medical billing.

Use of primary and preventive care services have declined sharply among children in Medicaid and the Children’s Health Insurance Program since the COVID-19 public health emergency, according to preliminary data released by the Centers for Medicare & Medicaid Services.

Sens. Dick Durbin, D-Ill., and Catherine Cortez Mastro, D-NV, introduced the Worker Health Coverage Protection Act, AHA-supported legislation that would subsidize COBRA and other health coverage for workers who lose employment-based coverage or are furloughed due to the pandemic.

The AHA urged the Department of Health and Human Services to reinstate the COVID-19 Provider Relief Fund reporting requirements outlined in its June 19 FAQ that defined both expenses and lost revenues attributable to COVID-19.

More than 200,000 of our friends, family members, fellow citizens and front-line workers have succumbed to COVID-19 since March. To put that in context, that’s approximately the same as the population of Salt Lake City, Utah.

AHA’s latest Members in Action podcast dives into the importance of promoting race equity to ensure healthy pregnancies, healthy babies and better outcomes for the community in general.

The Health Resources and Services Administration’s Federal Office of Rural Health Policy is accepting comments through Oct. 23 on proposed changes to how it designates geographic areas eligible for its rural health grants.

AHA Sept. 23 sponsored the Congressional Black Caucus Foundation Annual Legislative Conference session, “Advancing Black Maternal Health: Moving the Momnibus and Coverage Expansion Forward.”

The Department of Health and Human Services through Sept. 24 has reduced by 52.8% its backlog of Medicare appeals at the Administrative Law Judge level, according to a status report the agency provided today to a federal court.

Hospitals and health systems nationwide can participate in the non-partisan Spirit of Liberty Foundation’s Operation Thank You relay.

The Food and Drug Administration authorized for emergency use the first serology test to help identify individuals with antibodies to SARS-CoV-2 at the point of care.

The Blue Cross Blue Shield insurance group has reached a tentative settlement in an antitrust lawsuit dating back to 2012 that alleged its member companies illegally conspired to divvy up markets and avoid competing against one another, driving up customers’ prices, the Wall Street Journal reports.

The Department of Health and Human Services in a strongly worded letter to Eli Lilly calls into question recent actions by the drug manufacturer to limit 340B hospital and community clinics’ use of 340B contract pharmacy arrangements.